Tests amniotic stem cells in people with calciphylaxis
Tests amniotic stem cell therapy in adults with calciphylaxis, a rare condition of calcium damage.
Plain-language title generated from the registry record
Registry title: Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Key facts
- Where
- Nanjing, ChinaSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04592640, who can take part
Where in China
- The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province HospitalNanjing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The First Affiliated Hospital with Nanjing Medical University
- Trial code
- NCT04592640
- Record updated
- 4 March 2026
- Original description
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem CellsRead full original descriptionShow less
Effects of Human Amniotic-derived Mesenchymal Stem Cells (hAMSCs) on Calciphylaxis Patients: An Open-Label Single-Arm Study
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
Inclusion: 18-75 years old; Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis); All subjects signed informed consent.
Exclusion: Participation in another clinical trial with an experimental drug within 90 days prior the inclusion; Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months; Pregnant or lactating women of childbearing age; Patients who refuse to sign informed consent.